University Hospital Basel
Basel, Switzerland
I am Nazanin Tatari, a translational postdoctoral fellow at the University Hospital Basel in Switzerland.
Having completed a master’s degree in Immunology followed by 18 months of work experience in translational pediatric neuro-oncology setting at the University of Manitoba (Canada), I joined the laboratory of Dr. Sheila Singh located at the Centre for Discovery in Cancer Research (CDCR) of McMaster University (Canada) as a Ph.D. student where I focused on characterizing recurrent Glioblastoma (GBM) and its cognate tumor immune microenvironment using an integrated multi-omics platform to instruct novel and rational combinatorial poly-therapeutic approaches for the treatment of therapy-resistant GBM. For this purpose, I performed extensive amount of preclinical and translational research focused on drug target identification, biomarker discovery, immuno-oncology, generating and testing the anti-tumor efficacy of adoptive cell therapies (CAR-T cells and Bi-specific T-cell engager antibodies) against novel tumor associated antigens in GBM. Following completion of my PhD in September 2021, my passion for translational and clinical research in the field of brain tumor cell therapy led me to joining the Brain Tumor Immunotherapy Program at the University Hospital Basel in Switzerland as a translational postdoctoral fellow to further learn how to design clinical trials based on preclinical data and take discoveries from bench to bedside. As a translational neuro-oncology postdoctoral fellow, I have been focused on generating and testing novel adoptive cell therapies, particularly CAR-T cells using the novel virus free sleeping beauty transposon system for GBM patients from preclinical to clinical stage.
